Pharmacopeia Drug Discovery Company Profile

00:44 EDT 19th March 2018 | BioPortfolio

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic partnerships are with Cephalon, GlaxoSmithKline, Organon and Wyeth.


3000 Eastpark Blvd.
New Jersey
United States of America


Phone: 609-452-3600
Fax: 609-452-3672

News Articles [1846 Associated News Articles listed on BioPortfolio]

How Robot Math and Smartphones Led Researchers to a Drug Discovery Breakthrough

NewsResearchers have figured out how to apply an algorithm originally designed to help robots move to an entirely different problem: drug discovery.

Is Your Practice Ready for New Rules on Hazardous Drug Management

Among community oncology practices, the US Pharmacopeia Convention’s General Chapter <800> draft guidelines have already raised the bar for hazardous drug management and imposed costs for ...

The Current issue of “The view from here” is concerned with nanoscience in drug discovery.

The topic of this month’s newsletter from Drug Discovery Today is “nanoscience in drug discovery”

Blue Oak and PsychoGenics partner on drug discovery

Blue Oak Pharmaceuticals and PGI Drug Discovery have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions. Under the terms of the agreeme...

The Current issue of “The view from here” is concerned with Regulatory aspects of Drug Discovery.

The topic of this month’s newsletter from Drug Discovery Today is “Regulatory aspects of Drug Discovery”.

A Popular Tool for Drug Discovery Just Got 10 Times Faster

NewsResearchers at Purdue University just made high throughput screening, a process often used in drug discovery, 10 times faster than previous methods.

Beacon enters drug discovery collaboration with Janssen

US-based drug discovery firm Beacon Discovery has entered a multi-year collaboration agreement with Janssen Pharmaceuticals for small molecule compounds to...Read More... The post Beacon enters drug d...

X-Chem, AstraZeneca expand drug discovery partnership

X-Chem, a small molecule discovery specialist, has expanded its existing global drug discovery and technology transfer collaboration with AstraZeneca.

PubMed Articles [3001 Associated PubMed Articles listed on BioPortfolio]

Protac-induced Protein Degradation in Drug Discovery: Breaking the Rules - or Just Making New Ones?

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer the...

From machine learning to deep learning: progress in machine intelligence for rational drug discovery.

Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence...

Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors.

Phosphodiesterases are proving to be fruitful targets for drug discovery. At the same time fragment-based drug discovery has matured into a powerful and widely applied technique. In this communication...

Allosteric Tuning of Caspase-7: a Fragment-Based Drug Discovery Approach.

The caspase family of cysteine proteases are highly sought after drug targets due to their essential roles in apoptosis, proliferation and inflammation pathways. High throughput screening efforts to d...

Pathway-based technologies for early drug discovery.

Although the traditional drug discovery approach has led to the development of many successful drugs, the attrition rates remain high. Recent advances in systems-oriented approaches (systems-biology a...

Clinical Trials [2179 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

Endometriosis Biomarker Discovery Study

This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients unde...

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

The purpose of the study is to better understand the function of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms. In Phase I, our propose ...

Biologic Basis of Liver Cancer From Chronic Hepatitis B

The focus of the study is to identify viral factors and host immune responses that differentiate HBV-related HCC patients from HBV patients who have not progressed to HCC. To that end, the...

Companies [2342 Associated Companies listed on BioPortfolio]

Pharmacopeia Incorporated

Pharmacopeia, Inc. is a leader in enabling technology and technology-based services that accelerate drug discovery and chemical development. Pharmacopeia's laboratory services segment - Pharmacopeia L...

Pharmacopeia Drug Discovery

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independen...


Pharmacopeia is a biopharmaceutical company developing small molecule therapeutics to meet the needs of large patient populations suffering from significant unmet medical needs. With multiple internal...

Molecular Simulations Incorporated

Molecular Simulations Inc., a subsidiary of Pharmacopeia, Inc., is a leading provider of molecular modeling, simulation, and informatics software to the world’s foremost pharmaceutical, biotechnolog...


ZBChem is A member of Zhejiang ZhongBao I/E Corp.,Ltd Since 1963.ZBChem is the biggest China Excipients supplier and also supply many kinds of Cosmetic raw materials, Intermediates and API’s Guaran...

More Information about "Pharmacopeia Drug Discovery" on BioPortfolio

We have published hundreds of Pharmacopeia Drug Discovery news stories on BioPortfolio along with dozens of Pharmacopeia Drug Discovery Clinical Trials and PubMed Articles about Pharmacopeia Drug Discovery for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmacopeia Drug Discovery Companies in our database. You can also find out about relevant Pharmacopeia Drug Discovery Drugs and Medications on this site too.

Quick Search


Relevant Topic

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Corporate Database Quicklinks

Searches Linking to this Company Record